Citations

Showing 10 of 108094 citations.

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
Casulo, Carla , Santoro, Armando , Ando, Kiyoshi , Izutsu, Koji , Rule, Simon , Ruan, Jia , Arcaini, Luca , Casadebaig, Marie‐Laure, Fox, Brian A. , Kilavuz, Nurgul, Rettby, Nils , Dell’Aringa, Justine, Taningco, Lilia, Delarue, Richard, Czuczman, Myron S., Izutsu, Koji , Witzig, T.E. , Santoro, Armando , Casulo, Carla , Arcaini, Luca , Cartron, Guillaume , Muñoz, Javier , Gouill, Steven Le , Lugtenburg, Pieternella Johanna , Witzig, Thomas E.

Mayo Clinic

Cancer Reports | July 19, 2022 | Volume: 6 | Issue: 1 | Pages: No page available

10.1002/cnr2.1662 | PMID 35852004 Get It

AbstractBackgroundStudies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies.AimsPhase 1/2 FUSION NHL 001 was designed to determine the safety and efficacy of durvalumab, an anti‐programmed death ligand 1 (PD‐L1) antibody, combined with standard‐of‐care therapies for lymphoma or chronic lymphocytic leukemia (CLL).Methods and ResultsThe primary endpoints were to determine the recommended phase 2 dose of the drugs used in combination with durvalumab (durvalumab was administered at the previously recommended dose of 1500 mg every 4 weeks) and to assess safety and tolerability. Patients were enrolled into one of four arms: durvalumab monotherapy (Arm D) or durvalumab in combination with lenalidomide ± rituximab (Arm A), ibrutinib (Arm B), or rituximab ± bendamustine (Arm C). A total of 106 patients with relapsed/refractory lymphoma were enrolled. All but two patients experienced at least one treatment‐emergent adverse event (TEAE); those not experiencing a TEAE were in Arm C (diffuse large B‐cell lymphoma [DLBCL]) and Arm D (DLBCL during the durvalumab monotherapy treatment period). No new safety signals were identified, and TEAEs were consistent with the respective safety profiles for each study treatment. Across the study, patients with follicular lymphoma (FL; n = 23) had an overall response rate (ORR) of 59%; ORR among DLBCL patients (n = 37) was 18%. Exploratory biomarker analysis showed that response to durvalumab monotherapy or combination therapy was associated with higher interferon‐γ signature scores in patients with FL (p = .02).ConclusionDurvalumab as monotherapy or in combination is tolerable but requires close monitoring. The high rate of TEAEs during this study may reflect on the difficulty in combining durvalumab with full doses of other agents. Durvalumab alone or in combination appeared to add limited benefit to therapy.
Multiply robust Bayesian procedures for causal inference problems
Gochanour, Benjamin R. , Chen, Sixia , Beebe, Laura A.

Mayo Clinic

Communications in Statistics - Simulation and Computation | July 19, 2022 | Volume: 53 | Issue: 7 | Pages: 3271-3284

10.1080/03610918.2022.2101065 Get It

A Case Report of a Wenckebach Phenomenon Occurring during a His-Bundle Pacing Procedure: Is It Atrioventricular Node Pacing?
Ma, Chengming , Li, Wen-wen , Cha, Yong‐Mei , Xia, Yunlong , Gao, Lianjun , Dong, Yingxue, Li, Wenwen , Cha, Yongmei

Mayo Clinic

Journal of Cardiovascular Development and Disease | July 19, 2022 | Volume: 9 | Issue: 7 | Pages: 231

10.3390/jcdd9070231 | PMID 35877593 Get It

A 70-year-old man with severe valvular cardiomyopathy, permanent atrial fibrillation (AF) with a slow ventricular response, and transient atrioventricular (AV) block, was admitted to our center for severe heart failure and recurrent presyncope. While hospitalized, the coronary computed tomography angiography (CTA) showed huge atriums. We tried His bundle pacing (HBP). HB potential was observed at site A, and the His-ventricular (HV) interval was 68 ms. The duration from the stimulus signal to the onset of paced QRS (S-QRSonset) at site A was 232 ms when pacing at 60 beats per minute (BPM) with the pacing threshold of 2.0 V/0.5 ms. The S-QRSonset was longer than the HV interval and had a notable and progressive prolongation from 252 ms to 456 ms during the pacing at 90 BPM. Then, we pushed another lead a little forward, and the S-QRSonset shortened back to 68 ms, and the paced QRS morphology was the same as the intrinsic QRS morphology with the pacing threshold of 1.5 V/0.5 ms. The progressively prolonged S-QRSonset demonstrated a Wenckebach phenomenon (WP), a well-known electrophysiological characteristic of the AV node (AVN). It is the first time to report an intraoperative AVN-pacing related-WP in a patient with persistent AF. The enlarged atrium might be convenient for capturing the AVN. There are some other potential explanations for this phenomenon. The diameters of atriums decreased significantly, and the symptoms improved after the procedure. This is the first reported case in which we might achieve AVN capture in a patient with persistent AF. Although we ultimately chose HBP for better long-term pacing thresholds, the result of this case suggested that AVN pacing may be possible.
Microscopic colitis: Etiopathology, diagnosis, and rational management
Nielsen, Ole Haagen , Sato, Toshiro , Pardi, Darrell S. , Fernández-Bañares, Fernando

Mayo Clinic

eLife | July 19, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.79397 | PMID 35913459 Get It

Microscopic colitis is an inflammatory bowel disease divided into two subtypes: collagenous colitis and lymphocytic colitis. With an increasing incidence of microscopic colitis exceeding those of ulcerative and Crohn’s disease among elderly people in some countries, microscopic colitis is a debilitating life experience. Therefore, physicians should be familiar with its clinical features and management strategies because the disease deserves the same attention as the classical inflammatory bowel diseases. Here, state-of-the-art knowledge of microscopic colitis is provided from a global perspective with reference to etiopathology and how to establish the diagnosis with the overall aim to create awareness and improve rational management in clinical practice. The immune system and a dysregulated immune response seem to play a key role combined with risk factors (e.g. cigarette smoking) in genetically predisposed individuals. The symptoms are characterized by recurrent or chronic nonbloody, watery diarrhea, urgency, weight loss, and a female preponderance. As biomarkers are absent, the diagnosis relies on colonoscopy with a histological assessment of biopsy specimens from all parts of the colon. Although the disease is not associated with a risk of colorectal cancer, a recent nationwide, population-based cohort study found an increased risk of lymphoma and lung cancer. Budesonide is the first-line therapy for management, whereas immunomodulatory drugs (including biologics) and drugs with antidiarrheal properties may be indicated in those failing, dependent, or intolerant to budesonide. In microscopic colitis induced by checkpoint inhibitors, a drug class used increasingly for a wide range of malignancies, a more aggressive therapeutic approach with biologics introduced early seems reasonable. However, particular attention needs to be drawn to the existence of incomplete forms of microscopic colitis with the risk of being overlooked in routine clinical settings.
Comment on: Treatment strategies for clozapine-induced hypotension: A systematic review
Wieruszewski, Patrick M. , Wittwer, Erica D. , Leung, Sarah B., Leung, Jonathan G. , Leung, Jonathan G , Wieruszewski, Patrick M

Mayo Clinic

Therapeutic Advances in Psychopharmacology | July 19, 2022 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/20451253221111682 | PMID 35874555 Get It

Spironolactone, fibrosis and heart failure with preserved ejection fraction
Reddy, Yogesh N.V. , Sundaram, Varun , Nishimura, Rick

Mayo Clinic

European Journal of Heart Failure | July 19, 2022 | Volume: 24 | Issue: 9 | Pages: 1569-1572

10.1002/ejhf.2626 | PMID 35851716 Get It

Neglected Tropical Diseases and Sudden Cardiac Death: The NET-Heart Project
Miranda‐Arboleda, Andrés F. , González-Barrera, Luis Gerardo , Liblik, Kiera , Farina, Juan M. , Zaidel, Ezequiel , Saldarriaga, Clara , Zhou, Zier , Al-Rawi, Reem , Juárez-Lloclla, Jorge P., Gupta, Shyla, Kumar, Rajesh, Sosa-Liprandi, Álvaro , Farina, Juan M , Juarez-Lloclla, Jorge , López-López, José , Prabhakaran, Dorairaj , Baranchuk, Adrián

Mayo Clinic

Reviews in Cardiovascular Medicine | July 19, 2022 | Volume: 23 | Issue: 7 | Pages: No page available

10.31083/j.rcm2307254 | PMID 39076906 Get It

Sudden cardiac death (SCD) is responsible for approximately 6% of global mortality and 25% of cardiovascular (CV) deaths. SCD has been traditionally linked to coronary artery disease, valvular heart disease, cardiomyopathies, and genetic arrhythmia disorders. However, advancements in care for these diseases have not translated to a proportional reduction in SCD. This suggests an important role of underrecognized contributing pathologies. Neglected tropical diseases (NTDs) are a group of illnesses prevalent in tropical and sub-tropical regions which have been understudied partially due to their high prevalence in marginalized populations. The relationship between SCD and Chagas disease has been well-established, though emerging literature suggests that other NTDs with CV involvement may lead to fatal arrhythmias. Additionally, specific therapies for a subset of NTDs put patients at increased risk of malignant arrhythmias and other cardiac complications. This review aims to summarize the association between a group of selected NTDs and SCD.
Echocardiography in Cardiac Assist Devices
Anand, Senthil, Barry, Timothy, LeMond, Lisa , Arsanjani, Reza

Mayo Clinic

Reviews in Cardiovascular Medicine | July 19, 2022 | Volume: 23 | Issue: 7 | Pages: No page available

10.31083/j.rcm2307253 | PMID 39076924 Get It

In patients with medically refractory heart failure or cardiogenic shock, both temporary and durable mechanical circulatory support devices can be used to support cardiac circulation. Both transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) are widely available, relatively noninvasive, and avoid radiation exposure. Thus, echocardiography is an invaluable tool that provides vital information aiding in preprocedure evaluation, placement, management, and weaning of cardiac assist devices. The purpose of this article is to review the utility of both TTE and TEE in managing patients with cardiac assist devices.
Resilience or denial? Handling ethical dilemmas in the pediatric transplantation community
Johnson, Jonathan N.

Mayo Clinic

Pediatric Transplantation | July 19, 2022 | Volume: 26 | Issue: 7 | Pages: No page available

10.1111/petr.14325 | PMID 35851735 Get It

What Is the Role of Microglial Metabolism in Inflammation and Neurodegeneration?
Benarroch, Eduardo E.

Mayo Clinic

Neurology | July 18, 2022 | Volume: 99 | Issue: 3 | Pages: 99-105

10.1212/wnl.0000000000200920 | PMID 35851556 Get It